Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.

@article{SanchezReyes2004UseOS,
  title={Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.},
  author={L. K. Sanchez-Reyes and Guillermo Fangh{\"a}nel and Jorge Yamamoto and Lourdes Mart{\'i}nez-Rivas and Enrique Campos-Franco and Arturo Berber},
  journal={Clinical therapeutics},
  year={2004},
  volume={26 9},
  pages={1427-35}
}
BACKGROUND The management of type 2 diabetes mellitus is complicated by the presence of risk factors related to overweight and obesity, particularly visceral adiposity. However, weight loss and weight maintenance are difficult for patients with diabetes, and the benefits of dietary modifications are typically modest. Sibutramine is a serotonin- and norepinephrine-reuptake inhibitor that reduces food intake by inducing early satiety and attenuates the decrease in basal energy expenditure… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.

Obesity reviews : an official journal of the International Association for the Study of Obesity • 2009
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…